Seer (SEER) Set to Announce Quarterly Earnings on Wednesday

Seer (NASDAQ:SEER) is scheduled to announce its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Seer has set its FY 2024 guidance at EPS.Individual that wish to listen to the company’s earnings conference call can do so using this link.

Seer (NASDAQ:SEER) last announced its earnings results on Thursday, February 29th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.07. Seer had a negative net margin of 517.84% and a negative return on equity of 20.87%. The firm had revenue of $4.44 million for the quarter, compared to the consensus estimate of $4.24 million. On average, analysts expect Seer to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Seer Price Performance

Shares of SEER stock opened at $2.24 on Tuesday. Seer has a 52 week low of $1.46 and a 52 week high of $5.65. The firm has a 50 day moving average of $1.87 and a two-hundred day moving average of $1.77.

Insider Buying and Selling

In other news, CEO Omid Farokhzad sold 52,857 shares of the firm’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $2.03, for a total value of $107,299.71. Following the sale, the chief executive officer now directly owns 1,436,285 shares in the company, valued at approximately $2,915,658.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 15.02% of the stock is owned by insiders.

Analyst Ratings Changes

Separately, Morgan Stanley reissued an “equal weight” rating and set a $7.00 target price on shares of Seer in a research note on Tuesday, March 5th.

About Seer

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.